Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 2Endocrine 2CNS 2Breast 2Sarcoma 1NET 1Gynecologic 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1

Interventions

Everolimus 3tislelizumab 1surufatinib 1romidepsin 1regorafenib 1pembrolizumab 1pasireotide 1lutetium Lu 177 dotatate 1folfirinox 1fludarabine phosphate 1epothilone B 1cixutumumab 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Radiosurgery 1Octreotide 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Lactones 1LY2584702 1Interleukin-13 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Erlotinib Hydrochloride 1Embolization, Therapeutic 1Doxorubicin 1Depsipeptides 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Filgrastim × NET × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡